Full Text
Longitudinal Analysis Of Adjusted EQ-5D Utility Score At Baseline, Progression-Free Survival, And Progression For Lenvatinib Versus Sorafenib

Abstract

Authors

S Hudgens R Copher G Meier

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×